Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | IDH2 | P48735 | 3/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16807808 | 0.87 | IDH1 (0.32) | XPO1IDH1IDH2 | |
| SCHEMBL20303649 | 0.85 | PDE2A (0.38) | XPO1P2RX7CYP11B1CYP11B2IDH1 | |
| SCHEMBL21733739 | 0.81 | KDM4E (0.41) | XPO1 | |
| SCHEMBL21139917 | 0.78 | CYP3A4 (0.37) | XPO1IDH1IDH2TRPA1 | |
| SCHEMBL12763753 | 0.77 | KIF11 (0.31) | XPO1TRPA1 | |
| SCHEMBL27627609 | 0.76 | ABHD6 (0.34) | XPO1 | |
| SCHEMBL25163406 | 0.74 | CYP11B2 (0.39) | CYP11B2CASR | |
| SCHEMBL22062851 | 0.74 | CYP1A2 (0.42) | XPO1 | |
| SCHEMBL22489583 | 0.74 | CYP1A2 (0.45) | XPO1 | |
| SCHEMBL16256879 | 0.74 | CYP11B1 (0.37) | XPO1CYP11B1CYP11B2ADRB2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | XPO1 1355/4885P2RX7 3611/4885CYP11B1 1860/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | XPO1 1566/4885P2RX7 3488/4885CYP11B1 1945/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | XPO1 1355/4885P2RX7 3611/4885CYP11B1 1860/4885 |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | XPO1 1355/4885P2RX7 3611/4885CYP11B1 1860/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | XPO1 1355/4885P2RX7 3611/4885CYP11B1 1860/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | XPO1 1355/4885P2RX7 3611/4885CYP11B1 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.